DaVita Inc. (DVA) $145.58
DaVita has seen a 28% surge over the last three months, but a recent 5.5% pullback in April now tests critical support. Is this the dip you’ve been waiting for, or does more downside loom?
52-wk High $159.42
π Investment Snapshot
- π° DVA trades at $145.58, sporting a 15.31x P/E, a discount to the S&P 500 average.
- π Latest quarter revenue hit $3.62B with EPS at $3.29, demonstrating robust sequential growth.
- π Recent insider buying activity, including significant CEO share acquisition, signals strong internal confidence.
- π― Analysts project a mean target of $151.71, suggesting a +4.2% upside from current levels.
DVA recently pulled back after a strong 3-month rally, now trading near its 50-day SMA. While insider buying signals confidence, the stock isn’t yet oversold enough for a high-conviction entry.
| π Entry Zone | $144.00 or below | π Stop-Loss | $138.00 |
| π Adjust If | DVA reclaims $150 with increased volume, signaling renewed upward momentum. | ||
The Investment Case β Why Now?
DaVita’s shares have experienced a remarkable 28.1% ascent over the past three months, only to shed 5.5% in the last month. This recent pullback positions the stock at a critical juncture, testing the conviction of both bulls and bears. The significant insider buying on March 13, 2026, particularly the CEO’s acquisition of 20,900 shares, strongly suggests management sees value at these levels, aligning their interests with shareholders.
However, the primary risk to this thesis remains the evolving regulatory landscape in healthcare. Potential changes to Medicare or Medicaid reimbursement rates could directly impact DaVita’s profitability and revenue streams. Furthermore, rising interest rates, as indicated by the 10Y Treasury at 4.31%, elevate borrowing costs for capital-intensive healthcare providers, potentially compressing margins.
π€ Could DaVita’s recent insider activity signal a deeper value proposition than current market sentiment suggests, or is this simply routine compensation?
π’ Company Overview
| Detail | Value |
|---|---|
| Company | DaVita Inc. |
| Ticker / Exchange | DVA / NYSE |
| Sector / Industry | Healthcare / Medical Care Facilities |
| CEO | Javier J Rodriguez |
| Founded / HQ | 1999 / Denver, CO |
π Price Action & Technicals
Dead Cross
Inside VA
A buy-side sweep at $147.21 on March 13, 2026, indicates institutional interest above current price.
DVA currently trades at $145.58, positioned above both its 50-day ($143.04) and 200-day ($131.96) simple moving averages, signaling a longer-term uptrend. However, the price has dipped below the lower Bollinger Band ($146.28), an extreme condition that often precedes a short-term bounce or consolidation.
The RSI at 40.8 suggests mild weakness but avoids deeply oversold conditions, while the MACD’s bearish cross (1.7 below its 2.9 signal line) confirms recent downward momentum. The ADX at 13.2 indicates a weak trend, with the -DI (19.9) surpassing the +DI (11.1), reinforcing the bearish bias in the current pullback.
The Anchored VWAP from January 14, 2026, at $138.11, sits well below the current price, acting as a potential strong support level. The Volume Profile’s Point of Control (POC) at $130.21, with the Value Area spanning $115.02 to $154.75, suggests the current price remains within a zone of high trading activity, though closer to the upper boundary.
Volume currently runs 1.22x its 20-day average, indicating elevated interest during this pullback. While a bearish FVG at $151.19~$152.08 remains open above, a bullish FVG at $141.56~$144.34 presents a potential re-entry zone. The Technical Confluence Score of 80/100 underscores strong technical alignment, particularly from VWAP, Volume Profile, and recent liquidity sweeps, despite the ADX’s neutral stance.
π€ Given the conflicting technical signalsβa bearish MACD cross and ADX showing weak trend, yet price dipping below the lower Bollinger Bandβwhich indicator holds more sway for your short-term trading decisions?
β Peer P/E Comparison
| Ticker | Company | P/E (TTM) |
|---|---|---|
| DVA | DaVita Inc. | 15.31x |
| FMS | Fresenius Medical Care | 13.5x |
| HCA | HCA Healthcare | 17.0x |
| UHS | Universal Health Services | 15.0x |
| S&P 500 | Index Average | 21.0x |
π° Earnings Deep Dive
| Period | Revenue | EPS | YoY |
|---|---|---|---|
| Q4 2025 | $3.62B | $3.29 | +5.85% |
| Q3 2025 | $3.42B | $2.04 | +1.18% |
| Q2 2025 | $3.38B | $2.58 | +4.97% |
| Q1 2025 | $3.22B | $2.00 |
DaVita generated $0.4B in Free Cash Flow in the latest quarter, deploying a substantial $0.3B towards share buybacks. This aggressive capital allocation strategy underscores management’s confidence and commitment to enhancing shareholder value.
π Growth Drivers β What Moves the Stock
- Aging Demographics & CKD Prevalence π’ Upside Surprise β The increasing global prevalence of chronic kidney disease (CKD) coupled with an aging population drives a consistent demand for dialysis services. DaVita, as a market leader, stands to benefit directly from this demographic tailwind.
- Value-Based Care Expansion π‘ Priced In β DaVita’s strategic shift towards value-based care models, focusing on integrated kidney care, positions it favorably for long-term growth. These models incentivize better patient outcomes and cost efficiencies, potentially expanding margins.
- Strategic Partnerships & Innovation π’ Upside Surprise β Continuous innovation in treatment modalities and strategic partnerships with healthcare systems can enhance DaVita’s market reach and service offerings. This includes advancements in home dialysis and digital health solutions.
π€ With DaVita’s strong focus on value-based care, how effectively can they navigate potential reimbursement pressures while still driving innovation and market expansion?
π¦ Smart Money & Institutional Positioning
13F Holdings
| Institution | Shares (K) |
|---|---|
| Berkshire Hathaway, Inc | 31,759 |
| Vanguard Group Inc | 4,154 |
| Blackrock Inc. | 2,926 |
| Invesco Ltd. | 1,683 |
| Morgan Stanley | 1,477 |
Holdings reflect most recent 13F (45-day lag).
Insider Transactions
| Name | Title | Date | Type | Shares |
|---|---|---|---|---|
| RODRIGUEZ JAVIER J | Chief Executive Officer | Mar 13, 2026 | Acquisition | 20,900 |
| BERRY CHRISTOPHER MICHAEL | Officer | Mar 13, 2026 | Acquisition | 3,649 |
| WATERS KATHLEEN ALYCE | Officer | Mar 13, 2026 | Acquisition | 3,185 |
| SCHECHTER ADAM H | Director | Mar 13, 2026 | Acquisition | 332 |
Short Interest
| Short % Float | Days to Cover |
|---|---|
| 0.2% | 6.6 |
β Key Risk Factors
Significant revenue impact
Margin pressure
Increased debt service
Market share erosion
π― Guidance & Wall Street View
| High Target | Mean Target | Low Target | Analysts | Consensus |
|---|---|---|---|---|
| $190.0 | $151.71 | $126.0 | 7 | Hold |
| Firm | Rating | Target | Date | Action |
|---|---|---|---|---|
| UBS | Buy | Feb 2026 | Maintains | |
| Barclays | Equal-Weight | Feb 2026 | Maintains | |
| TD Cowen | Hold | Nov 2025 | Maintains | |
| B of A Securities | Underperform | Sep 2025 | Maintains |
The analyst consensus leans towards a Hold rating, reflecting a cautious stance despite recent strong performance. The mean target of $151.71 suggests limited upside from current levels, indicating analysts believe much of the positive news is already priced in.
π Bull vs Bear β Probability-Weighted Scenarios
π Bull Case
- Accelerated adoption of value-based care models drives higher patient retention and improved outcomes, boosting profitability beyond current expectations.
- Successful expansion into new international markets or strategic acquisitions consolidate market share and diversify revenue streams.
π Base Case
Our base case aligns with the analyst consensus, projecting steady growth in dialysis demand and continued operational efficiencies. We anticipate DaVita will maintain its market position, with modest revenue expansion and consistent cash flow generation, leading to a fair value near the mean target.
π» Bear Case
- Significant adverse changes in government reimbursement policies or increased regulatory scrutiny severely impact DaVita’s profitability.
- Intensified competition, particularly from emerging home dialysis providers or new market entrants, erodes market share and pricing power.
π― Investor Action Plan β By Profile
Stay on the sidelines for now. A high-conviction entry emerges if DVA pulls back to the $141.50-$144.00 range, targeting the open bullish FVG, with a tight stop below $138.00.
Await a clearer entry signal. Consider scaling into a position if DVA retests the $143.00 (SMA50) or $138.00 (Anchored VWAP) levels, confirming strong support for a longer-term hold.
While DaVita’s long-term thesis remains compelling, current valuation and technicals suggest patience. Look for a dip towards the $138.00-$144.00 range to initiate or add to a position, aligning with the bullish FVG and key moving averages.
β Investor FAQ β People Also Ask
Q: Why is DaVita’s P/E ratio lower than the S&P 500 average?
DaVita’s P/E of 15.31x sits below the S&P 500 average of 21x, reflecting sector-specific risks such as regulatory pressures and reimbursement uncertainties inherent in the healthcare services industry. While growth is stable, these factors often lead to a valuation discount compared to broader market indices.
Q: What do the recent insider transactions indicate?
The cluster of insider acquisitions on March 13, 2026, including a significant purchase by the CEO, signals strong internal confidence in DaVita’s future prospects. While not open market buys, these awards align management’s interests with shareholders and suggest a belief in the company’s underlying value.
Q: Is DVA currently oversold, given its price below the lower Bollinger Band?
While DVA’s price dipping below the lower Bollinger Band ($146.28) is a strong technical indicator of an oversold condition in the very short term, the RSI at 40.8 does not confirm deep oversold territory. This divergence suggests a potential for a bounce, but also indicates that the selling pressure might not be fully exhausted yet, warranting a ‘WAIT’ approach.
π For real-time updates and advanced charting tools,
π Disclaimer
This analysis is for informational purposes only and does not constitute financial advice. Investing in securities involves risks, and past performance is not indicative of future results. Always conduct your own due diligence and consult with a qualified financial advisor before making any investment decisions.
All active positions and their real-time performance are tracked on our Investment Log.
#DVA #DaVita #HealthcareStocks #StockAnalysis #USStocks #MedicalCare #InvestmentStrategy #TechnicalAnalysis